Dashboard
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Operating profit has grown by an annual rate 5.98% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -10.64
2
Flat results in Mar 25
3
Risky -
Stock DNA
Pharmaceuticals & Biotechnology
SEK 147 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
0.11
183.45%
-8.00
Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-20 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-55.93%
0%
-55.93%
6 Months
48.57%
0%
48.57%
1 Year
43.65%
0%
43.65%
2 Years
12.55%
0%
12.55%
3 Years
-85.48%
0%
-85.48%
4 Years
-93.77%
0%
-93.77%
5 Years
-83.09%
0%
-83.09%
Klaria Pharma Holding AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
60.86%
EBIT Growth (5y)
5.98%
EBIT to Interest (avg)
-10.64
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.90
Sales to Capital Employed (avg)
0.68
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-6.54
EV to EBIT
-4.66
EV to EBITDA
-8.41
EV to Capital Employed
-5.81
EV to Sales
11.77
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
0.00
9.00
-100.00%
Operating Profit (PBDIT) excl Other Income
-9.20
5.70
-261.40%
Interest
5.60
4.60
21.74%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-20.10
-1.60
-1,156.25%
Operating Profit Margin (Excl OI)
0.00%
332.40%
-33.24%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -100.00% vs 718.18% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -1,156.25% vs 89.74% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
2.20
8.50
-74.12%
Operating Profit (PBDIT) excl Other Income
-20.10
-21.40
6.07%
Interest
16.40
3.70
343.24%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-47.80
-35.80
-33.52%
Operating Profit Margin (Excl OI)
-13,916.80%
-3,832.20%
-1,008.46%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -74.12% vs 44.07% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -33.52% vs 43.89% in Dec 2023
About Klaria Pharma Holding AB 
Klaria Pharma Holding AB
Pharmaceuticals & Biotechnology
Klaria Pharma Holding AB (publ) is a Sweden-based holding company engaged in the biotechnology and medical research industry. Through its group subsidiaries, the Company is active in developing and commercializing therapeutic drugs and treatment methods in the fields of migraine and pain related to cancer based on a patented drug delivery platform in the form of an alginate-based polymer film, which facilitates rapid and reliable transmucosal absorption via a muco-adhesive film. The Company operates Klaria Pharma AB as a wholly owned subsidiary.
Company Coordinates 
Company Details
Virdings Alle 2 , UPPSALA None : 754 50
Registrar Details






